[The Aftercare Principle for Metastasizing Prostate Cancer. Few Diagnostics, Much Support]

Overview

Journal Urologe A

Specialty Urology

Date 2005 Aug 13

PMID 16096743

Citations 1

Authors

K Heine

J M Wolff

Affiliations

Soon will be listed here.

Abstract

For advanced prostate cancer - not including intermittent strategies - the patient is in continual treatment. The effect of the therapy must be controlled so that its failure can be determined as soon as possible and a new regimen started. As in most cases the progression of the disease can not be stopped, the aim of the therapy is to provide the patient with the best possible quality of life. In order to carry out therapy, if possible in the patient's usual environment, supportive therapies should be used, such as compensation for anaemia or pain therapy as required. Skeletal complications can be prophylactically treated by the use of biphosphonates.

Citing Articles

[Diagnostic work-up of bone metastases of genitourinary tumors and their treatment with bisphosphonates. Interdisciplinary consensus conference, Frankfurt, 2006].

Weissbach L Urologe A. 2006; 45(12):1527-31.

PMID: 17091278 DOI: 10.1007/s00120-006-1229-x.

References

Stuben G, Thews O, Pottgen C, Knuhmann K, Vaupel P, Stuschke M . Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol. 2001; 127(6):346-50. DOI: 10.1007/s004320000215. View

Greenberg M . Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 98(3):259-60. DOI: 10.1016/j.tripleo.2004.08.001. View

Dearnaley D, Sydes M, Mason M, Stott M, Powell C, Robinson A . A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003; 95(17):1300-11. DOI: 10.1093/jnci/djg038. View

Petrylak D, Scher H, Li Z, Myers C, Geller N . Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer. 1992; 70(12):2870-8. DOI: 10.1002/1097-0142(19921215)70:12<2870::aid-cncr2820701225>3.0.co;2-f. View

Rudat V, Dietz A, Schramm O, Conradt C, Maier H, Flentje M . Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol. 2000; 53(2):119-25. DOI: 10.1016/s0167-8140(99)00119-x. View

Migliorati C, Schubert M, Peterson D, Seneda L . Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005; 104(1):83-93. DOI: 10.1002/cncr.21130. View

Frommhold H, Guttenberger R, Henke M . The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol. 1999; 174 Suppl 4:31-4. View

Littlewood T, Bajetta E, Nortier J, Vercammen E, Rapoport B . Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19(11):2865-74. DOI: 10.1200/JCO.2001.19.11.2865. View

Ercole C, Lange P, Mathisen M, Chiou R, Reddy P, Vessella R . Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol. 1987; 138(5):1181-4. DOI: 10.1016/s0022-5347(17)43543-9. View

10.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

11.

Thews O, Koenig R, Kelleher D, Kutzner J, Vaupel P . Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer. 1998; 78(6):752-6. PMC: 2062974. DOI: 10.1038/bjc.1998.572. View

12.

Werner-Wasik M, Scott C, Cox J, Sause W, Byhardt R, Asbell S . Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000; 48(5):1475-82. DOI: 10.1016/s0360-3016(00)00801-4. View

13.

Kuban D, Sigfred S, Schellhammer P, Babb T . Characteristics of spinal cord compression in adenocarcinoma of prostate. Urology. 1986; 28(5):364-9. DOI: 10.1016/0090-4295(86)90062-2. View

14.

Dawson-Hughes B . Bone loss accompanying medical therapies. N Engl J Med. 2001; 345(13):989-91. DOI: 10.1056/NEJM200109273451310. View

15.

Messing E, Thompson Jr I . Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Urol Clin North Am. 2003; 30(4):687-702, viii. DOI: 10.1016/s0094-0143(03)00050-8. View

16.

Silver D, Piver M . Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol. 1999; 73(2):280-4. DOI: 10.1006/gyno.1999.5368. View

17.

Oefelein M, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H . Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001; 166(5):1724-8. DOI: 10.1016/s0022-5347(05)65661-3. View

18.

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

19.

Lissoni P, ROVELLI F, Baiocco N, Tangini G, Fumagalli L . A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res. 2001; 21(1B):777-9. View

20.

Smith M, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169(6):2008-12. DOI: 10.1097/01.ju.0000063820.94994.95. View